[go: up one dir, main page]

AR038563A1 - Composicion de ziprasidona y controles sinteticos - Google Patents

Composicion de ziprasidona y controles sinteticos

Info

Publication number
AR038563A1
AR038563A1 ARP030100527A ARP030100527A AR038563A1 AR 038563 A1 AR038563 A1 AR 038563A1 AR P030100527 A ARP030100527 A AR P030100527A AR P030100527 A ARP030100527 A AR P030100527A AR 038563 A1 AR038563 A1 AR 038563A1
Authority
AR
Argentina
Prior art keywords
ziprasidone
ziprasidone composition
synthetic controls
composition
synthetic
Prior art date
Application number
ARP030100527A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27761437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR038563(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR038563A1 publication Critical patent/AR038563A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pyridine Compounds (AREA)

Abstract

Composición de ziprasidona que comprende no más que aproximadamente 1000 ppm de ziprasidona desclorada, preferiblemente no más que aproximadamente 500 ppm de ziprasidona desclorada, y más preferiblemente no más que aproximadamente 100 ppm de ziprasidona desclorada. Se proporcionan también procedimientos para sintetizar y utilizar dichas composiciones de ziprasidona.
ARP030100527A 2002-02-20 2003-02-18 Composicion de ziprasidona y controles sinteticos AR038563A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35880602P 2002-02-20 2002-02-20
US35903802P 2002-02-21 2002-02-21
US36045902P 2002-02-27 2002-02-27

Publications (1)

Publication Number Publication Date
AR038563A1 true AR038563A1 (es) 2005-01-19

Family

ID=27761437

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100527A AR038563A1 (es) 2002-02-20 2003-02-18 Composicion de ziprasidona y controles sinteticos

Country Status (41)

Country Link
EP (1) EP1476162B1 (es)
JP (1) JP4554938B2 (es)
KR (1) KR100773622B1 (es)
CN (2) CN101735212A (es)
AP (1) AP2004003103A0 (es)
AR (1) AR038563A1 (es)
AT (1) ATE359787T1 (es)
AU (2) AU2003206035A1 (es)
BR (1) BR0307833A (es)
CA (1) CA2475302C (es)
CO (1) CO5611138A2 (es)
CY (1) CY1106467T1 (es)
DE (1) DE60313289T2 (es)
DK (1) DK1476162T3 (es)
EA (1) EA007866B1 (es)
EC (1) ECSP045239A (es)
ES (1) ES2283745T3 (es)
GE (1) GEP20074030B (es)
GT (1) GT200300040A (es)
HR (1) HRP20040711A2 (es)
IL (1) IL163277A (es)
IS (1) IS7344A (es)
MA (1) MA27177A1 (es)
MX (1) MXPA04006993A (es)
MY (1) MY139523A (es)
NO (2) NO20043902L (es)
NZ (1) NZ534443A (es)
OA (1) OA12774A (es)
PA (1) PA8567001A1 (es)
PE (1) PE20030942A1 (es)
PL (1) PL372238A1 (es)
PT (1) PT1476162E (es)
RS (1) RS60404A (es)
SI (1) SI1476162T1 (es)
SV (1) SV2004001485A (es)
TN (1) TNSN04159A1 (es)
TW (1) TW200307546A (es)
UA (1) UA77057C2 (es)
UY (1) UY27668A1 (es)
WO (1) WO2003070246A1 (es)
ZA (1) ZA200406276B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU780006B2 (en) 2000-03-06 2005-02-24 Acadia Pharmaceuticals, Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
DE60236206D1 (de) 2001-12-28 2010-06-10 Acadia Pharm Inc Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
EP1562937A2 (en) 2002-06-24 2005-08-17 Acadia Pharmaceuticals Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
AU2003300814A1 (en) 2002-12-04 2004-06-23 Dr. Reddy's Laboratories Inc. Polymorphic forms of ziprasidone and its hydrochloride
BRPI0406591B8 (pt) 2003-01-16 2021-05-25 Acadia Pharm Inc composto e composição farmacêutica
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
CA2519490A1 (en) 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd Polymorphis of valsartan
WO2004094392A1 (en) * 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valsartan
US7678799B2 (en) 2003-06-03 2010-03-16 Teva Pharmaceutical Industries Ltd. Crystalline ziprasidone HCl and processes for preparation thereof
US7667037B2 (en) 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
US20050197347A1 (en) * 2003-12-18 2005-09-08 Judith Aronhime Polymorphic form B2 of ziprasidone base
ES2334800T3 (es) * 2004-02-27 2010-03-16 Ranbaxy Laboratories Limited Proceso para la preparacion de ziprasidona.
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
EP1794126B1 (en) 2004-09-27 2013-03-20 Acadia Pharmaceuticals Inc. Crystalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide hemi-tartrate
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
ES2250000B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Procedimiento para la preparacion de ziprasidona.
EP1841764A1 (en) * 2005-01-27 2007-10-10 Hetero Drugs Limited Process for ziprasidone using novel intermediates
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
CN100491375C (zh) * 2006-07-01 2009-05-27 浙江美诺华药物化学有限公司 一种齐拉西酮的制备方法
US20090053329A1 (en) 2007-03-19 2009-02-26 Acadia Pharmaceuticals, Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
CN102234272A (zh) * 2010-04-21 2011-11-09 上海医药工业研究院 盐酸齐拉西酮半水合物的制备方法
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
WO2017015272A1 (en) 2015-07-20 2017-01-26 Acadia Pharmaceuticals Inc. Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
CN108239085A (zh) * 2016-12-26 2018-07-03 四川科瑞德凯华制药有限公司 一种甲磺酸齐拉西酮的纯化及制备方法
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
CN112724066B (zh) * 2021-02-04 2022-10-21 海南鑫开源医药科技有限公司 一种盐酸齐拉西酮中间体中的二卤杂质及其制备方法
CN116046966A (zh) * 2023-01-17 2023-05-02 北京协和建昊医药技术开发有限责任公司 一种流动相配置装置及其配置方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5338846A (en) 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
CN1071324C (zh) 1995-11-07 2001-09-19 辉瑞大药厂 制备3－(1－哌嗪基)－1,2－苯并异噻唑的方法和中间体
EA001180B1 (ru) * 1996-05-07 2000-10-30 Пфайзер Инк. Тригидрат мезилата 5-(2-(4-(1,2-бензизотиазол-3-ил)пиперазин-1-ил)этил)-6-хлор-1,3-дигидро-2н-индол-2-она, фармацевтическая композиция и способ лечения психического расстройства
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
RS60404A (en) 2006-10-27
CO5611138A2 (es) 2006-02-28
CA2475302A1 (en) 2003-08-28
EA007866B1 (ru) 2007-02-27
IL163277A (en) 2010-05-31
CY1106467T1 (el) 2012-01-25
ZA200406276B (en) 2005-09-20
CN101735212A (zh) 2010-06-16
UY27668A1 (es) 2003-10-31
NO20043902L (no) 2004-09-17
PE20030942A1 (es) 2003-11-08
MXPA04006993A (es) 2004-11-10
DK1476162T3 (da) 2007-07-02
CA2475302C (en) 2009-05-12
WO2003070246A1 (en) 2003-08-28
EP1476162A1 (en) 2004-11-17
NO20100584L (no) 2004-09-17
GT200300040A (es) 2007-01-12
NZ534443A (en) 2007-07-27
BR0307833A (pt) 2004-12-07
OA12774A (en) 2006-07-04
HRP20040711A2 (en) 2004-12-31
GEP20074030B (en) 2007-02-12
EP1476162B1 (en) 2007-04-18
MY139523A (en) 2009-10-30
SV2004001485A (es) 2004-05-07
KR20040086417A (ko) 2004-10-08
JP4554938B2 (ja) 2010-09-29
AU2003206035A1 (en) 2003-09-09
AU2009202008A1 (en) 2009-06-11
EA200400815A1 (ru) 2004-12-30
AP2004003103A0 (en) 2004-09-30
PT1476162E (pt) 2007-06-25
TNSN04159A1 (fr) 2007-03-12
TW200307546A (en) 2003-12-16
ATE359787T1 (de) 2007-05-15
ECSP045239A (es) 2004-09-28
DE60313289T2 (de) 2007-12-27
IS7344A (is) 2004-07-05
SI1476162T1 (sl) 2007-08-31
JP2005525347A (ja) 2005-08-25
PA8567001A1 (es) 2003-12-10
UA77057C2 (en) 2006-10-16
MA27177A1 (fr) 2005-01-03
ES2283745T3 (es) 2007-11-01
PL372238A1 (en) 2005-07-11
DE60313289D1 (de) 2007-05-31
CN1635892A (zh) 2005-07-06
KR100773622B1 (ko) 2007-11-05

Similar Documents

Publication Publication Date Title
AR038563A1 (es) Composicion de ziprasidona y controles sinteticos
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
ATE469892T1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
DK1560812T3 (da) Aminocyclohexyletherforbindelser og anvendelser deraf
DE60019586D1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
DE50310579D1 (de) Furancarboxamide
MXPA04003755A (es) Endoprotesis vasculares.
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
MX2007013470A (es) Forma purificada de tanaproget.
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
UA83203C2 (uk) Тіазол-(бі)циклоалкілкарбоксаніліди, засіб на їх основі та застосування для боротьби з небажаними мікроорганізмами
ATE372330T1 (de) N-sulfonylurea-apoptosis-förderer
MXPA06003345A (es) Derivados de aminopiridina como inhibidores de la no-sintasa inducible.
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
DE50311756D1 (de) Mikrobizide oxathiincarboxamide
ATE394105T1 (de) Substituierte 4,5-dihydro-1,2,4-triazin-3-one, 1, 2,4-triazin-3-one sowie deren verwendung als fungizide und insektizide
DE50303586D1 (de) Methylthiophencarboxanilide
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
YU26001A (sh) Derivati ureidopiperidina kao selektivni antagonisti ljudskih nk3 receptora
CU23343A3 (es) Composición de ziprasidona y controles sintéticos
CR7418A (es) Composicion de ziprasidona y controles sinteticos

Legal Events

Date Code Title Description
FB Suspension of granting procedure